CNBC Healthy Returns

Registration and Continental Breakfast

Welcoming Remarks

Tyler Mathisen, Co-Anchor, “Power Lunch,” CNBC

The Gatekeeper: Opening Conversation with FDA Commissioner Scott Gottlieb

When he took the lead at the FDA, Scott Gottlieb was seen as a pro-pharma choice. His legacy thus far, however, has been far more complicated. He’s taken on market inefficiencies, is approving generics at a record pace and trying to bring down drug prices. We’ll talk to him about what’s next at the FDA, including his vision for attacking the opioid crisis and his plans to balance public safety with faster drug approvals.
Scott Gottlieb, M.D., Commissioner of Food and Drugs, U.S. FDA
Interviewer: Meg Tirrell, Biotech and Pharma Reporter CNBC

The Investor Angle: What We’re Excited About Now

Leading investors give brief presentations on what they view as the most exciting and investable opportunities in health care for 2018 and beyond.
Venture Capital: Esther Dyson, Executive Founder, Way to Wellville; Board Member, 23 and Me and Open Humans Foundation
M&A;: Christopher O'Connor, Partner, Perella Weinberg Partners
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street,", CNBC

Getting Personal: Why It Matters

Thirteen-year-old Paige Whorton lives her life with great gusto. “I like parasailing, exploring and ziplining — daredevil stuff,” she says with a giggle. But she developed debilitating, degenerative pain in her joints, and doctors couldn’t diagnose its cause. That’s where genetic testing and personalized medicine came in — and saved her life.
Paige Whorton
John Noseworthy, M.D., President and CEO, Mayo Clinic

Editing Ethically: Big Hopes And Big Fears About CRISPR

Few medical innovations have engendered as much excitement as CRISPR, but the gene-editing technology raises serious ethical questions: Will the power to edit our own DNA outpace our ability to decide as a society how far we want to go? In a global race for advancements, how do we balance the quest for innovation and better health against worries about “designer babies” and unleashing irreversible genetic changes?
Luke Dow, Ph.D., Assistant Professor of Biochemistry in Medicine, Weill Cornell Medicine
Jeffrey Kahn, Ph.D., Director, Johns Hopkins Berman Institute of Bioethics
Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC

Networking Break

Innovation at Scale: Is Bigger Better...or Worse?

Many of the most innovative companies in the pharmaceutical industry today are smaller, more agile companies that focus on a limited number of technologies to drive innovation. More than ever, pharma giants are buying these upstart ventures to spur research and development. Is there an inverse relationship between company size and innovation?
Abbie Celniker, Ph.D., Partner, Third Rock Ventures
Fred Hassan Special Limited Partner, Warburg Pincus; Chairman, Caret Group; Former Chairman and CEO, Schering-Plough
Jeff Jonas, M.D., CEO, SAGE Therapeutics
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street," CNBC

Onstage Demonstration: Virtual Treatment for Real Pain

Presenter: David Sackman, Co-Founder and Chairman, appliedVR

WWAD: What Will Amazon Do?

The news that Jeff Bezos’ behemoth was partnering with J.P. Morgan Chase and Berkshire Hathaway to create a new health care venture sent health insurance stocks plummeting. It’s just a hint at Amazon’s potential disruptive, transformative role in health care. What’s next, and what’s their endgame?
Faisal Mushtaq, CEO, Truveris
Bill George, Senior Fellow, Harvard Business School; Former Chairman and CEO, Medtronic
Julie Grant, Partner, Canaan Partners; Board Member, Biden Cancer Initiative
Moderator: Christina Farr, Technology and Health Reporter, CNBC.com

Lunch

Join us for lunch in the Terrace Room on the lobby level. Select tables will feature hosted discussions. Please see your programs and posted information for details.

Sponsor Remarks

Neil De Crescenzo, President and CEO, Change Healthcare

Capitalizing Cures: Do Investors Inhibit Innovation?

It costs billions of dollars to develop revolutionary treatments and cures at scale, and often the only place to get that much funding is in the public markets. Investors, however, are focused on quarterly results and often have little patience with clinical trial setbacks and the years-long process of developing drugs. Is there a way to address this conflict?
Tony Coles, M.D., Chairman and CEO, Yumanity Therapeutics
Alex Denner, Ph.D., Founding Partner and CIO, Sarissa Capital Management
Leonard S. Schleifer, M.D., Ph.D., Founder, President and CEO, Regeneron Pharmaceuticals
Moderator: Jim Cramer, Host, "Mad Money w/ Jim Cramer;" Co-Anchor, "Squawk on the Street," CNBC

The Investor Angle: What We’re Excited About Now

Leading investors give brief presentations on what they view as the most exciting and investable opportunities in health care for 2018 and beyond.
Private Equity: Todd B. Sisitsky, Managing Partner, TPG Capital
Private Investment: Andrew Farnum, Director of Program-Related Investments, Bill & Melinda Gates Foundation
Moderator: Tyler Mathisen, Co-Anchor, “Power Lunch,” CNBC

Onstage Demonstration: Alphabetizing Health Care

Presenter: Jessica L. Mega, M.D., M.P.H., Chief Medical Officer, Verily Life Sciences

Networking Break

Aligning Interests: New Models for Health Care Companies

With the urgent need to bring down the unsustainable costs of health care, many companies are pursuing toward M&A.; Some health economists and insurance companies are also seeking a change from fee-for-service to an outcome-based model, offering incentives for successful and efficient treatments. Quality over quantity. Will these measures indeed provide better outcomes at lower costs?
David Cordani, President and CEO, Cigna
Delos ‘Toby’ Cosgrove, M.D., Former President and CEO, The Cleveland Clinic
Moderator: Bertha Coombs, Correspondent, CNBC

Getting Personal: Why It Matters

How one cancer researcher turned his own myeloma diagnosis into an opportunity, giving others the potential for greater control – and better outcomes – over their own care.
C. Anthony Blau, M.D., Professor of Medicine, Division of Hematology, Co-Director, Institute for Stem Cell and Regenerative Medicine; Director, Center for Cancer Innovation, University of Washington School of Medicine; Founder, All4Cure

Data vs. Disease: New Approaches

Cancer: Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer and SVP, Oncology, Flatiron Health
Opioids: Kyu Rhee, M.D., VP and Chief Health Officer, IBM
Interviewer: Meg Tirrell, Biotech and Pharma Reporter, CNBC

I Wanna Live Forever: A Conversation with Craig Venter

One of the leading scientists of our time, J. Craig Venter has been on the cutting edge of science for more than two decades. His institute is a leading organization dedicated to genomic research, and he’s the co-founder, executive chairman and CEO of Human Longevity. His institute is a leading research organization dedicated to genomic research, and he’s the co-founder, chairman and CEO of Human Longevity. We’ll find out what this visionary sees on the horizon in health care, science and medicine.
J. Craig Venter, Ph.D., Co-Founder, Executive Chairman and CEO, Human Longevity; Founder, Executive Chairman and CEO, J. Craig Venter Institute
Interviewer: Joe Kernen, Co-Anchor, “Squawk Box,” CNBC

Cocktail Reception